Clinical Trials Browser

Interleukin-2 × Lymphoid × 1 year × Clear all

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

85 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT04155710 2025-12-24

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Phase 1 Completed

7 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05336409 2025-12-18

ELiPSE-1

Phase 1 Terminated

28 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05400122 2025-11-12

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1 Suspended

12 enrolled

GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cell

Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasm Metastasis, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07225439 2025-11-06

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 1 Not yet recruiting

15 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Lymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral

NCT04673617 2025-06-11

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

45 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

128 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT00994643 2025-04-30

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Phase 2 Completed

11 enrolled 9 charts

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Clinical Trials

FT819 in Subjects With B-cell Malignancies

SELECT-CAR-NK

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

ELiPSE-1

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

LuminICE-203

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma